Denenchofufutaba Gakuen, NTT Group Start a Joint Study to Create Smart Campus Solutions
NTT Group (Nippon Telegraph and Telephone Corporation (Hereinafter, NTT), NTT DATA Corporation, NTT COMWARE Corporation, NTT Communications Corporation, NTT Ltd., Nippon Telegraph and Telephone East Corporation (Hereinafter, NTT East)) will begin a joint study with Denenchofufutaba Gakuen in order to develop smart campus solutions that will provide safety and security at schools. NTT Group implements technology of public safety solution that will draw on the proven implementation for the City of Las Vegas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005916/en/
Solution Overview (Graphic: Business Wire)
1. Background
In recent years, there have been several crimes and incidents involving students in school facilities, and resulting in requests to improve safety measures in addition to crime prevention activities by national and local governments. Furthermore, with the introduction of new educational guidelines, the workload of teachers is increasing, and there is a growing need for efficient and effective safety measures according to those in the field of school education. In order to respond to such needs, NTT Group aims to develop smart campus solutions that contribute to the strengthening of school safety with Denenchofufutaba Gakuen. This will leverage ICT solutions based on the system integration and application development capabilities of the public safety experience gained by providing smart city solutions*1 to the City of Las Vegas, in the United States.
2. Outline of the Joint Study
This joint study aims to build a data aggregation infrastructure that enables situational awareness of danger in the school by using high-resolution video cameras, audio sensors and IoT devices, analyze and predict dangerous events for students, and verify the solutions that contribute to strengthening school safety measures.
(1) Solution Features
The first step starts with the implementation of a system to monitor and report the traffic of vehicles and establish a system to ensure the safety of students when they move between school buildings. Through the operation of this system, the future needs of safety measures and solutions are studied to create new solutions that enables situation analysis uses AI, machine learning technology and 5G related technology.
The data aggregation infrastructure is built on the architecture of NTT's innovative Cognitive Foundation ®*2, which enables the remote creation, management, and operation of ICT resources, from devices and networks to the cloud.
(2) Points to be verified through Joint Study
Based on the operation of the above solution, the following will be developed with Denenchofufutaba Gakuen.
1) Identification of safety measures in school facilities
2) Identification of technical issues in system integration and operations
3) Creation of solutions using ICT technology
4) Feasibility study as a repeatable campus solution
(3) Period and location of implementation
- Period: Start from February 2020
- Location: Denenchofufutaba Gakuen Campus
(4) Role of each company
|
NTT Group |
NTT |
Overall supervision and coordination among group companies |
|
NTT DATA |
Joint planning, environment set-up and solution implementation
|
|
|
NTT COMWARE |
Multi-Orchestrator delivery and technical support |
|
|
NTT Communications |
Provision of cloud environment and technical support, Support for Multi-Orchestrator installation |
|
|
NTT Ltd |
Support for deployment and technical support of smart city solutions as per the City of Las Vegas implementation |
|
|
NTT East |
Provision of access network, support for network related technologies |
|
|
Denenchofu Futaba Gakuen |
Joint study planning support (Providing issues and needs) |
|
3. For the Future
In the future, with the learning from this joint study with Denenchofufutaba Gakuen, NTT Group will contribute to the enhancement of school safety by creating new smart campus solutions in the second quarter of 2020.
*1 (press release) About the smart city solutions available in Las Vegas, USA
https://www.ntt.co.jp/news2018/1812/181208a.html
*2 "Cognitive Foundation" is a registered trademark of Nippon Telegraph and Telephone Corporation in Japan.
About NTT
NTT is a Global Technology and Business Solutions Provider. We help clients accelerate growth and innovate new digital business models of the future. We provide business consulting and technology services for global networks, cybersecurity, managed IT and applications, workplace, datacenter and cloud services all supported by our deep industry expertise and innovation.
As a top five Global IT Services provider, our globally diverse and inclusive workforce supports clients in 80+ countries and regions. This includes 85% of the Fortune Global 100 companies and thousands of other clients and communities. With a 120-year heritage of service, innovation and social responsibility, we always advocate and act for our clients and a sustainable future. For more information on NTT, visit www.global.ntt/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005916/en/
Contact information
Media Contacts
Nippon Telegraph and Telephone Corporation (NTT)
Public Relations Office
Tomoka Ito
E-mail: ntt-cnr-ml@hco.ntt.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom